MAPT and Alzheimer disease: In the present study, we have focused on GSK3-β as a potential target for AD therapy, which is responsible for phosphorylating Tau on residue S396, in which abnormal phosphorylation is considered to be an early marker of subsequent hyperphosphorylation [18].